Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPD | P32754 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097417 | 0.91 | FFAR1 (0.45) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13097421 | 0.90 | FFAR1 (0.44) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13097462 | 0.90 | DDB1 (0.41) | GRM5DHODHMAPT | |
| SCHEMBL13107299 | 0.89 | FFAR1 (0.42) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13097414 | 0.88 | PARP1 (0.45) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13097446 | 0.87 | MAP4K1 (0.42) | GRM5DHODHMAPT | |
| SCHEMBL3092081 | 0.83 | CYP2D6 (0.43) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13107346 | 0.81 | FFAR1 (0.44) | FFAR1FFAR4HTR1AHTR1DHTR1B | |
| SCHEMBL13097148 | 0.80 | KDM4E (0.49) | DHODHMAPT | |
| SCHEMBL13097461 | 0.80 | DDB1 (0.43) | GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | FFAR1 1105/4885FFAR4 838/4885HTR1A 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.